Safety concerns continue to plague Roche’s BTK inhibitor in RMS
Roche’s BTK inhibitor, fenebrutinib, cuts relapse rates in patients with relapsing multiple sclerosis (RMS), but safety concerns continue to cloud…
News
Xeltis gains EU CE mark on positive trial data for vascular access graft
AstraZeneca to seek accelerated approval of Ultomirisin in IgAN on Phase III data
MSD and Eisai’s RCC combination regimens fail to meet Phase III trial endpoints
Roche reports Phase III METEOROID study results for MOGAD
Paradigm Health debuts post-marketing study tool for routine care integration
Tenvie doses first subject in Phase I TNV108 trial for peripheral neuropathies
AstraZeneca’s COPD drug gains third Phase III win
